Biomea Fusion, Inc. (BMEA)
2.03
+0.12
(+6.28%)
USD |
NASDAQ |
Sep 04, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Total Liabilities (Quarterly) : 24.74M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.74M |
| March 31, 2026 | 27.67M |
| December 31, 2025 | 29.02M |
| September 30, 2025 | 39.57M |
| June 30, 2025 | 45.65M |
| March 31, 2025 | 26.32M |
| December 31, 2024 | 28.36M |
| September 30, 2024 | 34.45M |
| June 30, 2024 | 32.22M |
| March 31, 2024 | 33.18M |
| December 31, 2023 | 30.69M |
| September 30, 2023 | 25.48M |
| Date | Value |
|---|---|
| June 30, 2023 | 24.37M |
| March 31, 2023 | 29.51M |
| December 31, 2022 | 21.30M |
| September 30, 2022 | 14.42M |
| June 30, 2022 | 11.35M |
| March 31, 2022 | 10.10M |
| December 31, 2021 | 7.542M |
| September 30, 2021 | 8.072M |
| June 30, 2021 | 7.517M |
| March 31, 2021 | 59.65M |
| December 31, 2020 | 57.36M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| REGENXBIO, Inc. | 314.85M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 36.87M |
| Shareholders Equity (Quarterly) | 12.14M |
| Debt to Equity Ratio | 0.0723 |
| Current Ratio | 3.475 |
| Net Debt Paydown Yield | 1.32% |